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Abstract
Background: Mother-to-child transmission (MTCT) is the main cause of HIV-1 infection in children worldwide. Given that the
C-type lectin receptor, dendritic cell-specific ICAM-grabbing non-integrin-related (DC-SIGNR, also known as CD209L or liver/
lymph node–specific ICAM-grabbing non-integrin (L-SIGN)), can interact with pathogens including HIV-1 and is expressed at
the maternal-fetal interface, we hypothesized that it could influence MTCT of HIV-1.
Methods and Findings: To investigate the potential role of DC-SIGNR in MTCT of HIV-1, we carried out a genetic association
study of DC-SIGNR in a well-characterized cohort of 197 HIV-infected mothers and their infants recruited in Harare,
Zimbabwe. Infants harbouring two copies of DC-SIGNR H1 and/or H3 haplotypes (H1-H1, H1-H3, H3-H3) had a 3.6-fold
increased risk of in utero (IU) (P=0.013) HIV-1 infection and a 5.7-fold increased risk of intrapartum (IP) (P=0.025) HIV-1
infection after adjusting for a number of maternal factors. The implicated H1 and H3 haplotypes share two single nucleotide
polymorphisms (SNPs) in promoter region (p-198A) and intron 2 (int2-180A) that were associated with increased risk of both
IU (P=0.045 and P=0.003, respectively) and IP (P=0.025, for int2-180A) HIV-1 infection. The promoter variant reduced
transcriptional activity in vitro. In homozygous H1 infants bearing both the p-198A and int2-180A mutations, we observed a
4-fold decrease in the level of placental DC-SIGNR transcripts, disproportionately affecting the expression of membrane-
bound isoforms compared to infant noncarriers (P=0.011).
Conclusion: These results suggest that DC-SIGNR plays a crucial role in MTCT of HIV-1 and that impaired placental DC-SIGNR
expression increases risk of transmission.
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Introduction
Without specific interventions, the rate of HIV-1 mother-to-
child transmission (MTCT) is approximately 15–45% [1].
UNAIDS estimates that last year alone, more than 400,000
children were infected worldwide, mostly through MTCT and
90% of them lived in sub-Saharan Africa. In the most heavily-
affected countries, such as Zimbabwe, HIV-1 is responsible for one
third of all deaths among children under the age of five. MTCT of
HIV-1 can occur during pregnancy (in utero, IU), delivery
(intrapartum, IP) or breastfeeding (postpartum, PP). High
maternal viral load, low CD4 cells count, vaginal delivery, low
gestational age have all been identified as independent factors
associated with MTCT of HIV-1 [1]. Although antiretrovirals can
reduce MTCT to 2%, limited access to timely diagnostics and
drugs in many developing world countries limits the potential
impact of this strategy. A better understanding of the mechanisms
acting at the maternal-fetal interface is crucial for the design of
alternative interventions to antiretroviral therapy for transmission
prevention.
Dendritic cell-specific ICAM-grabbing non-integrin-related
(DC-SIGNR, also known as CD209L or liver/lymph node-specific
ICAM-grabbing non-integrin (L-SIGN)) can interact with a
plethora of pathogens including HIV-1 and is expressed in
PLoS ONE | www.plosone.org 1 October 2009 | Volume 4 | Issue 10 | e7211placental capillary endothelial cells [2]. DC-SIGNR is organized
in three distinct domains, an N-terminal cytoplasmic tail, a repeat
region containing seven repeat of 23 amino acids and a C-terminal
domain implicated in pathogen binding. Alternative splicing of
DC-SIGNR gene leads to the production of a highly diversify
isoforms repertoire which includes membrane-bound and soluble
isoforms [3]. It has been proposed that interaction between DC-
SIGNR and HIV-1 might enhance viral transfer to other
susceptible cell types [2] but DC-SIGNR can also internalize
and mediate proteasome-dependant degradation of viruses [4] that
may differently affect the outcome of infection.
Given the presence of DC-SIGNR at the maternal-fetal
interface and its interaction with HIV-1, we hypothesized that it
could influence MTCT of HIV-1. To investigate the potential role
of DC-SIGNR in MTCT of HIV-1, we carried out a genetic
association study of DC-SIGNR in a well-characterized cohort of
HIV-infected mothers and their infants recruited in Zimbabwe,
and identified specific DC-SIGNR variants associated with
increased risks of HIV transmission. We further characterized
the functional impact of these genetic variants on DC-SIGNR
expression and show that they affect both the level and type of
DC-SIGNR transcripts produced in the placenta.
Methods
Subjects
Samples consisted of stored DNA extracts obtained from 197
mother-child pairs co-enrolled immediately postpartum in the
ZVITAMBO Vitamin A supplementation trial (Harare, Zim-
babwe) and followed at 6 weeks, and 3-monthly intervals up to 24
months. The ZVITAMBO project was a randomized placebo-
controlled clinical trial that enrolled 14,110 mother-child pairs,
between November 1997 and January 2000, with the main
objective of investigating the impact of immediate postpartum
vitamin A supplementation on MTCT of HIV-1. The samples
used in the present study were from mother–child pairs randomly
assigned to the placebo group of the ZVITAMBO project.
Antiretroviral prophylaxis for HIV-1-positive antenatal women
was not available in the Harare public-sector during ZVITAMBO
patient recruitment. The samples were consecutively drawn from
two groups: 97 HIV-1-positive mother/HIV-1-positive child pairs
and 100 HIV-1-positive mother/HIV-negative child pairs.
Mother’s serological status was determined by ELISA and
confirmed by Western Blot. Infants were considered to be infected
if they were HIV-1 seropositive at 18 months or older and had two
or more positive HIV-1-DNA polymerase chain reaction (PCR)
results at earlier ages. 100 infants were considered to be uninfected
as they were ELISA negative at 18 months or older and had two
DNA PCR negative results from samples collected at a younger
age. Of the 97 HIV-1-infected infants, 57 were infected IU, 11
were infected IP, and 17 were infected PP as determined by PCR
analyses of blood samples collected at birth, 6 weeks, 3 and 6
months of age and according to the following definitions adapted
from Bryson and colleagues [5]. Briefly, infants who were DNA
PCR positive at birth were infected IU. Infants with negative PCR
results from sample obtained at birth but who become positive by
6 weeks of age were infected IP. Infants with negative PCR results
at birth and 6 weeks of age but who subsequently became DNA
PCR positive were considered to be infected during the PP period.
In the analysis comparing the 3 different modes of MTCT, 12
HIV-1-infected infants were excluded because the PCR results
were not available at 6 weeks of age. Full methods for recruitment,
baseline characteristics collection, laboratory procedures have
been described elsewhere [6].
DC-SIGNR haplotypes reconstruction, htSNPs selection
and genotyping
The nucleotide sequence variation of the entire promoter,
coding and part of 39-UTR regions of DC-SIGNR gene in the
study population was determined previously [7]. Haplotype
reconstruction was performed using Bayesian statistical method
implemented in PHASE [8], version 2.1.1, using single nucleotide
polymorphism (SNP) with a minimum allele frequency (MAF) of
2%. We applied the algorithm five times, using different randomly
generated seeds, and consistent results were obtained across runs
(Figure 1). Fifteen haplotype-tagged SNPs (htSNPs) were identified
by the HaploBlockFinder software [9] with a MAF $5%. These
htSNPs were genotyped in the 197 infants by direct PCR
sequencing analysis as we have described previously [7]. The
DC-SIGNR exon 4 repeat region genotype was determined by
PCR amplification followed by migration in 1.5% agarose gels
[10]. DNA sequences in the promoter region were analysed with
the TESS interface (http//:www.cbil.upenn.edu/tess) for putative
transcription factors binding sites using the TRANSFAC database.
Luciferase assays
Luciferase reporter assays using pGL2-Basic vector were
performed in order to investigate the functional effect of mutations
on DC-SIGNR promoter activity. Genomic DNA from subjects
homozygous for the promoter variants and WT was amplified
from nucleotide position 2715 to 21 and cloned between the
BglII and HindIII multiple cloning sites in the pGL2-Basic vector
which harbours a reporter firefly luciferase gene downstream
(Invitrogen Canada inc, Burlington, Canada). All recombinants
clones were verified by DNA sequencing. The firefly luciferase test
reporter vector was co-transfected at a ratio of 10:1 with the
constitutive expressor of Renilla luciferase, phRL-CMV (Promega,
Madison, WI, USA). We cultured HeLa cells in 6 wells plates
(2610
5 cells) and transfected them the following day using
lipofectamine (Invitrogen) according to the manufacturer. Cells
were lysed and luciferase assays were performed using 20 mgo f
protein extract according to the manufacturer (Promega) at 44 h
post-transfection. Firefly luciferase activity was normalized to
Renilla luciferase activity. 0 mg, 0,5 mgo r1mg CMV-Tat vector
was transfected with LTR-Luc as a positive control in these
experiments. We carried out lucierase assays in triplicate in three
independent experiments. Results are expressed as mean6
standard error of the mean (S.E.M).
DC-SIGNR isoforms repertoire
First-term placental tissues were obtained from abortions
following voluntary interruption of pregnancy at CHUM Ho ˆpital
Saint-Luc (Montreal, Canada). Tissues from 3 H1 (associated with
MTCT of HIV-1) and 3 H15 (wild-type) homozygous haplotypes
were used to analyse possible differences in isoform expression.
Total placental RNAs were extracted by MasterPure DNA and
RNA Extraction Kit (Epicentre Biotechnologies, Madison, WI,
USA) according to the manufacturer. Fragments corresponding to
the DC-SIGNR coding region were reversed transcribed (RT) and
then amplified by nested PCR with the following primers; RT
primers RR, first PCR RF and RR and second PCR RcF and
RcR according to Liu and colleagues [11]. 1 mg of total RNA was
reverse transcribed with Expand RT (Roche Applied Science,
Indianapolis, IN, USA) according to the manufacturer and were
PCR-amplified with DNA Platinum Taq Polymerase (Invitrogen).
Major PCR products from the second PCR reaction were gel
extracted with the Qiagen Gel Extraction Kit (Qiagen Canada inc,
Mississauga, ON, Canada) and cloned using the TOPO TA
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doi:10.1371/journal.pone.0007211.g001
DC-SIGNR Influences HIV-1 MTCT
PLoS ONE | www.plosone.org 3 October 2009 | Volume 4 | Issue 10 | e7211Cloning Kit for sequencing (Invitrogen). For each placenta, 15
different clones were randomly selected and amplified with M13
primers and sequenced with ABI PRISM 3100 capillary
automated sequencer (Applied Biosystems, Foster City, CA,
USA). Sequences were analysed and aligned with GeneBank
reference sequence NM_014257 using Lasergene software (DNA
Stars, Madison, WI, USA).
Quantitative expression of DC-SIGNR isoforms
1,5 mg of placental RNA was reverse transcribed using 2.5 mM
of Oligo dT20 and Expand RT in 20 ml volume according to the
manufacturer (Roche Applied Science). 15 ng of total cDNA in a
final volume of 20 ml was used to perform quantitative real-time
PCR using Universal Express SYBR GreenER qPCR Supermix
(Invitrogen) on a Rotor Gene Realtime Rotary Analyser (Corbett
Life Science, Sydney, Australia). Samples from 2 subjects in each
group were used because RNA quality of others was not suitable
for a qRT-PCR analysis. Amplification of all DC-SIGNR isoforms
was performed using an exon 5 specific primer pair (Table S1).
Membrane-bound isoforms were amplified using primers specific
for exon 3, corresponding to the common trans-membrane
domain of DC-SIGNR. Primers were targeted to the exon-exon
junction and RNA extracts were treated with DNase (Fermantas
International inc, Burlington, ON, Canada) to avoid amplification
of contaminant DNA. Standard curves (50–500 000 copies per
reaction) were generated using serial dilution of a full-length DC-
SIGNR or commercial GAPDH (Invitrogen) plasmid DNA. All
qPCR reactions had efficiencies ranging from 99% to 100%, even
in the presence of 20 ng of non-specific nucleic acids, and
therefore could be compared. The copy number of unknown
samples was estimated by placing the measured PCR cycle
number (crossing threshold) on the standard curve. To correct for
differences in both RNA quality and quantity between samples,
the expression levels of transcripts were normalised to the
reference GAPDH gene transcripts. GAPDH primer sequences
were kindly provided by A. Mes-Masson at the CHUM. The
results are presented as target gene copy number per 10
5 copies of
GAPDH. The ratio of membrane-bound isoforms was calculated
as E3/E5. Soluble isoforms were calculated by subtracting
membrane-bound from total isoforms. We carried out qPCR
assays in triplicate in three independent experiments. Results are
expressed as mean6S.E.M.
Statistical analysis
Statistical analysis was performed using the GraphPad PRISM
5.0 for Windows (GraphPad Software inc, San Diego, CA, USA).
Differences in baseline characteristics and genotypic frequencies of
haplotypes or htSNPs were compared between groups using the x
2
analysis or Fisher’s exact test. Logistic regression analysis was used
to estimate odds ratios (OR) for each genotype and baseline risk
factors. Multiple logistic regression was used to define independent
predictors identified as significant in the crude analysis. ORs and
95% confidence interval were calculated with the exact method.
Comparisons of continuous variables between groups were
assessed with the unpaired two-tailed Student’s t test when
variables were normally distributed and with the Mann-Whitney
U test when otherwise. Differences were considered significant at
P,0.05.
Ethics statement
Written informed consent was obtained from all mothers who
participated in the study and the ZVITAMBO trial and the
investigation reported in this paper were approved by The
Medical Research Council of Zimbabwe, The Medicines Control
Authority of Zimbabwe, The Johns Hopkins Bloomberg School of
Public Health Committee on Human Research, and the CHUM
and Montreal General Hospital Ethics Committees. First-term
placental tissues were obtained from abortions following voluntary
interruption of pregnancy at CHUM Ho ˆpital Saint-Luc (Mon-
treal, Canada) with written informed consent in accordance with
the CHUM Research Ethics Committee.
Results
We carried out an association study of DC-SIGNR polymor-
phism in 197 infants born to untreated HIV-1-infected mothers
recruited in Harare, Zimbabwe. Among them, 97 infants were
HIV-1-infected and 100 infants remained uninfected. Of the 97
HIV-1-infected infants, 57 were infected IU, 11 were infected IP,
and 17 were infected PP. Timing of infection was not determined
for 12 HIV-1-infected infants. Baseline characteristics of mothers
and infants are presented in Table 1. Maternal age and CD4 cell
count, child sex, mode of delivery, duration of membrane rupture
and gestational age were similar among all groups. However,
maternal viral load .29 000 copies/ml was associated with
increased risk in both IU and PP with odds ratios (OR) of 3.64
(95% CI=1.82–7.31, P=0.0002) and 4.45 (95% CI=1.50–13.2,
P=0.0045) for HIV-1 transmission, respectively.
Fifteen haplotype-tagged SNPs (htSNPs) corresponding to the
15 major DC-SIGNR haplotypes (Figure 1) described among
Zimbabweans [7] were genotyped in our study samples (Tables S2
and S3). H1 (31%) and H3 (11%) were the most frequent
haplotypes observed (Figure 1). Being homozygous for the H1
haplotype was associated with increased risk of both IU (OR: 4.42,
P=0.022) and PP (OR: 7.31, P=0.016) HIV-1 transmission
(Table 2). Infants harbouring two copy combinations of H1 and/
or H3 haplotypes (H1-H1, H1-H3 or H3-H3) had increased risk of
IU (OR: 3.42, P=0.007) and IP (OR: 5.71, P=0.025) but not PP
(P=0.098) HIV-1 infection compared to infant noncarriers
(Table 2). The latter associations remained significant after
adjustment was made for the maternal viral load for both IU
(OR: 3.57, 95% CI=1.30–9.82, P=0.013) and IP (OR: 5.71,
95% CI=1.40–23.3, P=0.025) HIV-1 transmission. The H1 and
H3 haplotypes share a cluster of mutations (p-198A, int2-391C,
int2-180A, ex4RPT, int5+7C) (Figure 1). Of these, the p-198A and
int2-180A variants were significantly associated with MTCT of
HIV-1 (Table S2). In the unadjusted regression analysis,
homozygous infants for the p-198A and int2-180A variants had
increased risk of IU (OR: 2.07 P=0.045, OR: 3.78, P=0.003,
respectively) and IP (OR: 2.47, P=0.17, O.R: 5.71, P=0.025,
respectively) HIV-1 infection compared to heterozygote infants or
noncarriers (Table 3). When adjustment was made for maternal
factors, only the association with the int2-180A variant remained
significant for IU (OR: 3.83, 95% CI=1.42–10.4, P=0.008) and
IP (O.R: 5.71, 95% CI=1.40–23.3, P=0.025) HIV-1 transmis-
sion. Thus, infants homozygous for DC-SIGNR variant int2-180A
contained in H1 and H3 haplotypes were 4-fold to 6-fold more
likely to be infected by HIV-1 during pregnancy or at delivery,
respectively.
Alternative splicing of the DC-SIGNR gene in the placenta
produces both membrane-bound and soluble isoform repertoires
[3]. The relative proportion of membrane bound and soluble DC-
SIGNR could plausibly influence the susceptibility to HIV-1
infection [11]. We therefore hypothesized that the DC-SIGNR
mutations associated with MTCT of HIV-1 would have an impact
on both the level of DC-SIGNR expression and in the isoform
repertoire produced. We investigated DC-SIGNR transcript
expression in first-term placentas obtained after elective abortion.
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homozygous H1 samples containing both the DC-SIGNR
p-198AA and int2-180AA variants associated with HIV-1
transmission and 3 homozygous wild-type (WT) (p-198CC, int2-
180GG) samples. Fifteen clones per sample were randomly
selected for sequencing. As expected, we found an extensive
repertoire of DC-SIGNR transcripts in all samples with 9 to 16
different isoforms per individual. A total of 65 distinct transcripts
were identified (Figure S1), of which 3 were full-length transcripts.
64 of the sequenced clones contained a total of 69 amino acid
substitutions with 3 new C termini and 2 premature stop codons.
However, the diversity was mostly attributable to the entire
deletion of exon 2 or exon 3 or to variations in the length of the
neck region (exon 4) of DC-SIGNR. The deletion of exon 3
eliminates the trans-membrane domain of the protein and leads to
the expression of soluble DC-SIGNR isoforms [3]. Interestingly,
the abundance of membrane-bound isoforms in placental tissues of
the H1 homozygotes appears to be lower than that observed in
samples from WT individuals (Figure S1). The deletion of exon 3
was confirmed by sequencing and we hypothesize that the skipping
of exon 3, could be due to the presence of the int2-180A mutation
observed in infants with the H1 haplotype. In fact, this intron
mutation is located 180 bp downstream from exon 3 and
potentially modifies splicing events (Figure 2A). We confirmed
that the variation in transcript proportions seen between the two
groups was also reflected at the level of mRNA expression in the
placenta. To quantify membrane-bound vs soluble isoforms in
placental samples from homozygous H1 and WT infants, we
amplified the exon 5 (E5) sequence present in all DC-SIGNR
isoforms (total transcripts). We then amplified exon 3 (E3) which is
deleted in the soluble forms and then calculated the E3:E5 ratio.
We found that placental tissues from homozygous H1 infants
express a significantly lower proportion of membrane-bound DC-
SIGNR (18%) compared to that in WT individuals (36%)
(P=0.004) (Figure 2B) suggesting that exon 3 skipping happens
more frequently in presence of the DC-SIGNR int2-180A variant
associated with MTCT of HIV-1.
The DC-SIGNR int2-180A variant is always transmitted with
the promoter mutation p-198A (Figure 1). In the unadjusted
regression analysis, the p-198A variant was significantly associated
with IU but not with IP and PP HIV-1 transmission (Table 3).
Computational transcription factor binding site analysis predicts
Table 1. Baseline characteristics of mother and infants risk factors for intrauterine (IU), intrapartum (IP) and postpartum (PP)
mother-to-child HIV-1 transmission.
Variables HIV - IU infection IP infection PP infection
% (N) % (N) OR (95% CI) % (N) OR (95% CI) % (N) OR (95% CI)
P value P value P value
Maternal age, mean
years 26 26 24 28
(SD) (25–27) (24–27) 0.53
a (22–28) 0.40
a (25–31) 0.26
a
Child’s sex
F 43 (42) 55 (31) 0.62 (0.32–1.20) 70 (7) 0.33 (0.08–1.34) 53 (8) 0.67 (0.22–1.99)
M 57 (55) 45 (25) 0.15
c 30 (3) 0.18
b 47 (7) 0.47
c
Gestational age (weeks)
$37 95 (94) 98 (55) 0.34 (0.04–3.00) 80 (8) 4.70 (0.78–28.2) 94 (16) 1.18 (0.13–10.7)
,37 5 (5) 2 (1) 0.42
b 20 (2) 0.12
b 6 (1) 1.00
b
Membrane rupture (hours)
0 – 3 57 (56) 49 (26) 1.39 (0.71–2.71) 50 (5) 1.33 (0.36–4.91) 50 (8) 1.33 (0.46–3.84)
.3 43 (42) 51 (27) 0.34
c 50 (5) 0.74
b 50 (8) 0.60
b
Mode of delivery
Vaginal 87 (87) 93 (52) 0.52 (0.16–1.66) 90 (9) 0.74 (0.09–6.37) 82 (14) 1.43 (0.36–5.68)
Caesarean 13 (13) 7 (4) 0.30
b 10 (1) 1.00
b 18 (3) 0.70
b
Maternal CD4 cell counts (cells/mm3)
$500 41 (35) 42 (20) 0.98 (0.48–2.01) 22 (2) 2.45 (0.48–12.5) 18 (3) 3.27 (0.87–12.2)
,500 59 (50) 58 (28) 0.96
c 78 (7) 0.47
b 82 (14) 0.098
b
Maternal CD4/CD8 cells ratio
$0.5 51 (43) 52 (25) 0.94 (0.46–1.91) 56 (5) 0.82 (0.21–3.26) 35 (6) 1.88 (0.64–5.54)
,0.5 49 (42) 48 (23) 0.87
c 44 (4) 1.00
b 65 (11) 0.25
c
Mothers’ viral loads (copies/ml)
#29,000 71 (68) 40 (22) 3.64 (1.82–7.31) 64 (7) 1.39 (0.37–5.12) 35 (6) 4.45 (1.50–13.2)
.29,000 29 (28) 60 (33) 0.0002
c 36 (4) 0.73
b 65 (11) 0.005
c
CI, Confidence interval; F, female; M, male; N, number; OR, odds ratio; SD, standard deviation.
aP value as determined by Mann-Whitney U test.
bP value as determined by the Fisher’s exact test.
cP value as determined by the x
2 test.
doi:10.1371/journal.pone.0007211.t001
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would affect a C/EBPbeta transcription factor binding site (TESS
web site). To test the effect of DC-SIGNR p-198A variant on
transcription, we transiently transfected HeLa cells with a
luciferase reporter gene under the control of DC-SIGNR promoter
region –715 to –1 with either C (WT) or A at position -198
(Figure 3A). The luciferase activity of the p-198A variant construct
was significantly lower than that of the WT p-198C promoter
construct (p-198C/A ratio=2, P=0.006) (Figure 3B) suggesting
that DC-SIGNR p-198A affects promoter activity. The other
promoter mutants (p-577C and p-323A) observed in the
Zimbabwean population did not affect DC-SIGNR transcription
in this assay (Figure S2). To determine the net impact of the DC-
SIGNR p-198A mutation on DC-SIGNR expression in the
placenta, we quantitated the absolute number of total and
membrane-bound DC-SIGNR transcripts in the H1 homozygote
and wild-type placental samples as described earlier. The total
number of DC-SIGNR transcripts was determined to be 6856213
(DC-SIGNR copies6S.E.M per 10
5 GAPDH copies) in the
placental samples from homozygous H1 infants and was 4-fold
lower compared to that found in placentas from WT individuals
(27816638, P=0.011) (Figure 3C). As suggested earlier, the int2-
180A mutation might induce exon 3 skipping leading to a lower
production of membrane-bound DC-SIGNR. Although, the
decrease in the total number of DC-SIGNR transcripts in H1
homozygous placental samples containing both the p-198AA and
int2-180AA variants affected the proportion of membrane-bound
and soluble isoforms, the effect of these mutations was more
pronounced on the membrane-bound isoforms with an 8-fold
decrease (H1=117636.2 vs WT=9906220.6, P=0.003) com-
pared to a 3-fold decrease in total soluble isoforms
(H1=5686181.9 vs WT=19256495.3, P=0.03) (Figure 3C).
Therefore, DC-SIGNR p-198A and int2-180A mutations associ-
ated with MTCT of HIV-1 significantly decreased the level of total
placental DC-SIGNR transcripts, disproportionately affecting the
membrane-bound isoform production.
Table 2. Associations between infant DC-SIGNR haplotypes and intrauterine (IU), intrapartum (IP) and postpartum (PP) mother-to-
child HIV-1 transmission.
Child DC-SIGNR haplotype genotypes HIV - IU infection IP infection PP infection
% (N) % (N) OR (95% CI) % (N) OR (95% CI) % (N) OR (95% CI)
P value P value P value
Haplotype H1
H1-other/other-other 96 (95) 84 (43) 4.42 (1.26–15.5) 82 (9) 5.28 (0.85–32.9) 76 (13) 7.31 (1.63–32.8)
H1-H1 4 (4) 16 (8) 0.022
a 18 (2) 0.11
a 24 (4) 0.016
a
Haplotype H3
H3-other/other-other 99 (98) 98 (50) 1.96 (0.12–32.0) 100 (11) NA 100 (17) NA
H3-H3 1 (1) 2 (1) 1.00
a 0 1.00
a 0 1.00
a
Haplotype H1-H3
H1-other/H3-other/
other-other 91 (90) 74.5 (38) 3.42 (1.35–8.68) 64 (7) 5.71 (1.40–23.3) 76 (13) 3.08 (0.83–11.5)
H1-H1/H1-H3/H3-H3 9 (9) 25.5 (13) 0.007
b 36 (4) 0.025
a 24 (4) 0.098
a
CI, Confidence interval; N, number; NA, not applicable; OR, odds ratio.
aP value as determined by the Fisher’s exact test.
bP value as determined by the x
2 test.
doi:10.1371/journal.pone.0007211.t002
Table 3. Associations between infant DC-SIGNR promoter p-198 and intron 2 (int2)-180 variants and intrauterine (IU), intrapartum
(IP) and postpartum (PP) mother-to-child HIV-1 transmission.
Child DC-SIGNR Mutations HIV - IU infection IP infection PP infection
% (N) % (N) OR (95% CI) % (N) OR (95% CI) % (N) OR (95% CI)
P value P value P value
p-198
CC/CA 75 (74) 59 (30) 2.07 (1.01–4.25) 54.5 (6) 2.47 (0.69–8.79) 59 (10) 2.07 (0.71–6.02)
AA 25 (25) 41 (21) 0.045
b 45.5 (5) 0.17
a 41 (7) 0.24
a
int2-180
GG/GA 91 (90) 72.5 (37) 3.78 (1.51–9.50) 64 (7) 5.71 (1.40–23.3) 76 (13) 3.08 (0.83–11.5)
AA 9 (9) 27.5 (14) 0.003
b 36 (4) 0.025
a 24 (4) 0.098
a
CI, Confidence interval; N, number; OR, odds ratio.
aP value as determined by the Fisher’s exact test.
bP value as determined by the x
2 test.
doi:10.1371/journal.pone.0007211.t003
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Our genetic results, supported by expression assay in placenta,
suggest the involvement of DC-SIGNR in MTCT of HIV-1.
Homozygosity for the haplotype H1 was associated with IU
transmission in the unadjusted regression analysis. However, the
association disappeared after adjustment was made for the
maternal factors presumably because of the small number of H1
homozygote infants analysed in each groups. H1 and H3 were the
most frequent haplotypes observed in the study population and
they share a cluster of mutations (Figure 1). Grouping haplotypes
H1 and H3 increased the power of the study and permitted the
identification of specific DC-SIGNR mutations associated with
MTCT of HIV-1. Indeed, two mutations shared by haplotypes H1
and H3 were associated with vertical transmission of HIV-1. The
int2-180A was associated with a 4-fold increased risk of IU and 6-
fold increased risk of IP after adjustment for the maternal factors.
Although the p-198A variant was associated with IU transmission,
the association disappeared after adjustment was made for the
maternal viral load. Nevertheless, we showed that this mutation
reduces DC-SIGNR transcriptional activity in vitro and produces
lower level of DC-SIGNR transcripts in placental tissues in
combination with the int2-180A variant. Since int2-180A is always
transmitted with p-198A on the MTCT associated combined
haplotypes H1/H3, whereas p-198A is carried on other non-
associated haplotypes (Figure 1), we can speculate that the p-198A
mutation alone may have a minor effect in vivo whereas in
combination with the int2-180A variant, they both act to reduce
the level of placental DC-SIGNR expression resulting in an
increased risk of MTCT of HIV-1.
The majority of IU transmission occurs during the last trimester
of pregnancy (reviewed in [12]). Full-term placenta samples were
not available for the current study and the expression assays were
performed on first-term placental tissues. A previous study looking
at DC-SIGNR placental isoforms repertoire in full-term placenta
samples demonstrated similar diversity of DC-SIGNR transcripts
as in the first-term placental tissues studied herein [3]. However,
since levels of DC-SIGNR expression have never been compared
between the different terms of pregnancy, it is not known whether
DC-SIGNR expression varies during the course of pregnancy.
Nevertheless, it is reasonable to assume that the inter-individual
differences in both DC-SIGNR isoform repertoire and transcript
levels observed between the H1 and WT homozygous infants
would be reflected throughout the pregnancy.
Figure 2. Effect of the int2-180A variant on placental DC-SIGNR isoform expression. (a) Schematic representation of the int2-180A variant
location within the DC-SIGNR gene. (b) Proportion of DC-SIGNR membrane-bound and soluble isoforms in homozygous H1 (int2-180AA) and
homozygous WT (int2-180GG) placental samples estimated by qRT-PCR assays in three independent experiments performed in triplicate. Data are
presented as percentage of total transcripts. Differences between isoform proportions among the homozygous H1 and homozygous WT were
calculated by the x
2 test.
doi:10.1371/journal.pone.0007211.g002
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PLoS ONE | www.plosone.org 7 October 2009 | Volume 4 | Issue 10 | e7211Figure 3. Transcriptional activity of DC-SIGNR promoters. (a, b) Effect of the p-198A variant on transcriptional activity in luciferase reporter
assay in vitro in transfected HeLa cells. (a) Schematic representation of reporter gene constructs corresponding to the DC-SIGNR promoter region
from –715 to –1, spanning with either C (WT) or A at position 2198. (b) Relative luciferase expression from pGL2-Basic, the parental vector without
the promoter. Expression of the DC-SIGNR promoter constructs were calculated relatively to this value. Data are presented in mean6S.E.M. values of
three independent experiments performed in triplicate and difference in relative luciferase expression between the p-198 variants was examined with
the Student’s t test. (c) Total number of DC-SIGNR isoforms in homozygous H1 (p-198AA, int2-180AA) and homozygous WT (p-198CC, int2-180GG)
placental samples measured by qRT-PCR assays in three independent experiments performed in triplicate. Data are shown in mean6S.E.M. copies
number normalized by 10
5 copies number of GAPDH. Student’s t test was used to calculate differences in the number of isoforms between the H1
and WT groups.
doi:10.1371/journal.pone.0007211.g003
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SIGNR in trans infection of HIV-1 in vitro [2,10]. However, the
multiple mechanisms involved in trans infection and redundancy
among C-type lectin functions make it difficult to determine the
actual participation of DC-SIGNR in this mode of infection in vivo
[13,14]. The strong correlation we observed between MTCT of
HIV-1 and DC-SIGNR genetic variants producing low levels of
DC-SIGNR in the placenta suggested that mechanisms other than
DC-SIGNR-mediated trans infection might operate during vertical
transmission of HIV-1. For example, DC-SIGNR has also been
shown to function as a HIV-1 antigen-capturing receptor [15].
Chan and colleagues recently demonstrated that DC-SIGNR
transfected CHO cells diminish SARS-CoV titers by enhanced
capture and degradation of the virus in a proteasome-dependent
manner [4]. Since endothelial cells express MHC-I and II,
degraded viral antigens could then be presented to immune cells to
elicit an adaptive immune response [16,17]. The HIV-1 co-
receptor CCR5, but not CD4, is co-expressed with DC-SIGNR on
placental and blood-brain barrier (BBB) endothelial cells [18,19].
HIV-1 gp120 binding to CCR5 receptor on endothelial cells
compromises BBB integrity and enhances monocytes adhesion
and transmigration across the BBB [20,21]. It is thus possible that
reduced expression of DC-SIGNR, particularly the membrane-
bound isoforms, on placental capillary endothelial cells might
favour HIV-1 binding to CCR5 receptor, instead of DC-SIGNR
receptor, facilitating the migration of maternal HIV-1-infected
cells across the placental barrier resulting in IU transmission of
HIV-1.
The int2-180A variant contained in the H1 and H3 haplotypes
was associated with IP transmission suggesting that DC-SIGNR
also affect transmission of HIV-1 during delivery. Little is known
about the mechanisms underlying transmission of HIV-1 during
delivery. Passage through the birth canal could potentially expose
infants through a mucosal portal entry (presumably ophthalmic,
skin, or gastrointestinal), whereas placental insult during delivery
(physical or inflammatory) may enhance transplacental passage of
maternal HIV-1-infected cells into foetal circulation [22,23]. Such
process called microtransfusion has been proposed in regards to
the results obtain in a Malawian cohort. Kweik and colleagues
found a significant association between levels of maternal DNA in
umbilical cord blood and IP transmission of HIV-1 suggesting that
passage of maternal infected cells through the placenta is likely to
occur during delivery [22]. Thus, in a similar fashion as suggested
earlier for IU transmission, the relatively lower level of DC-
SIGNR in the placenta of homozygous infants harbouring the
int2-180A variant could promote HIV-1 binding to CCR5
receptor on endothelial cells affecting the placental barrier
integrity and facilitating the passage of maternal infected cells in
foetal circulation during delivery.
Beside DC-SIGNR, other HIV-1 receptors are known to
influence MTCT of HIV-1 (reviewed in [24]). Genetic variants in
CCR5 have been shown to influence vertical transmission of HIV-
1. CCR5 promoter variants resulting in higher expression of the
receptor were associated with increased risk of MTCT of HIV-1
among sub-Saharan Africans [25,26]. The 32-pb deletion
polymorphism in CCR5 has be shown to protect from vertical
transmission of HIV-1 [27], but this variant is virtually absent
among African populations [28]. High copy numbers of CCL3L1,
a potent HIV-1 suppressive ligand for CCR5, are associated with
higher chemokine production and lower risk of MTCT of HIV-1
among South African infants [29,30]. Mannose-binding lectin
(MBL) is an innate immune receptor synthesised in the liver and
secreted in the bloodstream in response to inflammation signal.
MBL promotes pathogen elimination by opsonization and
phagocytosis, and reduced expression of MBL resulting from
polymorphism in coding and non-coding regions has been
associated with an increased risk of MTCT of HIV-1 [31,32].
In this study, we demonstrate for the first time, the potential
functional impact of DC-SIGNR mutations on its expression in
the placenta and in vertical transmission of HIV-1. We believe
that the presence of DC-SIGNR at the placental endothelial cell
surface may protect infants from HIV-1 infection by capturing
virus and promoting its degradation/presentation. However, in
placenta containing low levels of DC-SIGNR, HIV-1 would
preferentially binds CCR5 on endothelial cells resulting in a loss of
placental barrier integrity and enhanced passage of maternal HIV-
1-infected cells in foetal circulation leading to MTCT of HIV-1.
This mechanism may also apply to other vertically-transmitted
pathogens known to interact with DC-SIGNR such as HIV-2,
hepatitis C and dengue viruses and warrant further investigation.
Supporting Information
Table S1 Primer pairs and qRT-PCR conditions for DC-
SIGNR expression assays. a Accession number NM_014257, b
Accession number NM_002046
Found at: doi:10.1371/journal.pone.0007211.s001 (0.03 MB
DOC)
Table S2 Associations between child DC-SIGNR htSNPs and
mother-to-child HIV-1 transmission. CI, Confidence interval;
htSNPs, haplotypes-tagged single nucleotide polymorphisms; N,
number; OR, odds ratio, NA; not applicable, Del; deletion. a
P-value as determined by the Chi-square test.
Found at: doi:10.1371/journal.pone.0007211.s002 (0.09 MB
DOC)
Table S3 Associations between child DC-SIGNR exon 4
repeated region genotypes and mother-to-child HIV-1 transmis-
sion.CI, Confidence interval; N, number; NA; not applicable; OR,
odds ratio a P-value as determined by the Chi-square test. b
Comparison between genotype and all others.
Found at: doi:10.1371/journal.pone.0007211.s003 (0.05 MB
DOC)
Figure S1 DC-SIGNR transcripts repertoire in placenta. Major
RT-PCR products from RNA extract from 3 homozygous H1 and
3 homozygous WT placenta samples were purified, cloned and
sequenced. Sequenced were analysed according to NCBI
reference sequence NM_014257. CT; cytoplasmic tail, TM;
trans-membrane domain; WT; wild-type
Found at: doi:10.1371/journal.pone.0007211.s004 (0.11 MB
DOC)
Figure S2 Effect of DC-SIGNR promoter variant on transcrip-
tional activity in luciferase reporter assay in vitro in transfected
HeLa cells. Relative luciferase expression from pGL2-Basic,
parental vector without promoter. Expression DC-SIGNR
promoter constructs, spanning p-577C variant or p-323A variant
were calculated relatively to this value. Data are presented in mean
values6S.E.M of three independent experiments performed in
triplicate. One-way ANOVA test followed by the Dunnett test for
multiple comparison was used to compare the relative luciferase
expression of the p-557C and p-323A variant reporters against the
wild-type (WT) construct (not significant). 0 mg, 0,5 mgo r1mg
CMV-Tat vector was transfected with LTR-Luc as a positive
control in these experiments.
Found at: doi:10.1371/journal.pone.0007211.s005 (0.27 MB
DOC)
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